Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05042011
Other study ID # 2020-5316-14620
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2021
Est. completion date November 30, 2021

Study information

Verified date September 2021
Source Aga Khan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In order to improve routine immunization uptake during COVID-19 pandemic, and to understand the perceptions and barriers related to vaccine hesitancy and coverage during COVID 19 and to explore the need for COVID-19 vaccination, separately and as a part of routine immunization, the investigators will be using qualitative methodology to explore and understand the role of mHealth and social media interventions, that are most suitable in Pakistani context to improve vaccination coverage during COVID-19 pandemic.


Description:

The application of information and communication technologies (through such digital health methods as SMS, phone calls and automated calls, smartphone apps and wearable technology) has paved the way for modification of health-related knowledge and bring in the behavior change and practices to decrease vaccine hesitancy and improve immunization uptake. Mass and social media are influential in the dissemination of information regarding the COVID-19 pandemic, as well as the development and use of vaccines, not only for COVID-19 but also CRI. However, the same low-cost/free and accessible methods (social media platforms) that enable low/middle-income populations to communicate, connect and access information can also be the main factor in the distribution and prevalence of unregulated, unverified misinformation. In particular, the anti-vaccination movement, which has been identified as a major factor for vaccine hesitancy is the result of spreading misinformation through these same social media platforms. In light of the current pandemic and distancing measures, CRI coverage is adversely affected as caregivers avoid tertiary care hospitals or primary health centers. This has further increased the risk of outbreak for vaccine-preventable diseases, as well as economic burden due to morbidity and mortality and delay in caregiver getting back to work. A recent survey by an international consortium also illustrated a decline in vaccination coverage across all milestone age groups, except for vaccines administered at birth in hospital like Hepatitis B. Hence due to reduced vaccination rates, various countries are experiencing outbreaks of previously controlled diseases globally like measles, rubella, tuberculosis, and rotavirus, and has even caused new mutated strains of polio to reemerge. However, for the first time in almost three decades there has been the significant decrease in the coverage of DPT3 vaccine dose. Pakistan is identified as a LMIC with high vaccine hesitancy and is third among countries with the most unvaccinated/under-vaccinated children. It ranks fourth in global child mortality, with 60% of deaths due to infectious diseases that are vaccine-preventable. The EPI coverage for fully immunized children were estimated to be 65% and 88% at national level respectively in the past two survey reports. However, rates for Sindh province are even lower with fully immunized children rates of 39% and 80% respectively. Further Pakistan is among three polios endemic country and among top 5 countries with the most unvaccinated and under-vaccinated children. With further decrease in immunization rates due to current pandemic, vaccination coverage has only plummeted all time low coverage further due to disruption in vaccination services and demand, causing new outbreaks of previously controlled diseases like new polio strains, measles and rubella. Hence it is eminent to explore new strategies included mhealth and social media to bring in the behavior change in order to improve vaccine uptake. In addition, it is also important to understand the perceptions and barriers related to vaccine hesitancy and coverage during COVID 19 and come up with strategies to finalize our interventions.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date November 30, 2021
Est. primary completion date October 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Caregivers of children less than one year of age will be enrolled from HDSS sites. 2. Health care providers including (doctors, nurses, pharmacists, LHVs, Vaccinators, LHWs, etc.) will also be recruited from these sites. Exclusion Criteria: 1. The exclusion criteria include the children from outside the health demographic surveillance system (HDSS) area and if the family does not plan to stay in the catchment area. 2. Health care providers will be excluded who are from outside the HDSS.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Pakistan Aga Khan University Karachi Sindh

Sponsors (2)

Lead Sponsor Collaborator
Aga Khan University Yale University

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hesitancy towards childhood routine immunization (Interview) Questions To understand the perceptions and barriers related to routine immunization during COVID-19 pandemic 2 months
Primary COVID-19 vaccine hesitancy (Interview) Questions To understand the perceptions and barriers related to COVID-19 vaccine for adults and as part of routine immunization 2 months
Primary Role of mHealth and social media (Interview) Questions To understand the role of mHealth and social media in improving childhood immunization coverage and COIVD-19 vaccine during COVID-19 2 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3